I-Tech AB (ITECH.ST)
SEK 75.4
(-9.16%)
SEK 75.4
(-9.16%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 40.14 Million SEK | -91.06% |
| 2022 | 35.03 Million SEK | 7.98% |
| 2021 | 32.45 Million SEK | 3.94% |
| 2020 | 31.22 Million SEK | 6.09% |
| 2019 | 29.42 Million SEK | 19.43% |
| 2018 | 24.64 Million SEK | 86.89% |
| 2017 | 13.18 Million SEK | 8.14% |
| 2016 | 12.19 Million SEK | 46792.31% |
| 2015 | 26 Thousand SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 12.28 Million SEK | 11.1% |
| 2024 Q3 | 11.87 Million SEK | -3.32% |
| 2024 Q1 | 11.05 Million SEK | -26.75% |
| 2023 Q1 | 7.93 Million SEK | -35.97% |
| 2023 FY | 3.13 Million SEK | -91.06% |
| 2023 Q4 | 15.09 Million SEK | 74.01% |
| 2023 Q3 | 8.67 Million SEK | -12.95% |
| 2023 Q2 | 9.96 Million SEK | 25.5% |
| 2022 Q1 | 7.57 Million SEK | -15.69% |
| 2022 FY | 35.03 Million SEK | 7.98% |
| 2022 Q4 | 12.39 Million SEK | 92.38% |
| 2022 Q3 | 6.44 Million SEK | -25.3% |
| 2022 Q2 | 8.62 Million SEK | 13.95% |
| 2021 Q1 | 7.43 Million SEK | -23.95% |
| 2021 Q3 | 6.35 Million SEK | -34.42% |
| 2021 Q4 | 8.98 Million SEK | 41.37% |
| 2021 FY | 32.45 Million SEK | 3.94% |
| 2021 Q2 | 9.68 Million SEK | 30.33% |
| 2020 Q4 | 9.77 Million SEK | 42.7% |
| 2020 Q3 | 6.84 Million SEK | -9.47% |
| 2020 Q1 | 7.03 Million SEK | -22.8% |
| 2020 FY | 31.22 Million SEK | 6.09% |
| 2020 Q2 | 7.56 Million SEK | 7.5% |
| 2019 Q2 | 6.56 Million SEK | -8.01% |
| 2019 FY | 29.42 Million SEK | 19.43% |
| 2019 Q4 | 9.11 Million SEK | 37.94% |
| 2019 Q3 | 6.6 Million SEK | 0.59% |
| 2019 Q1 | 7.14 Million SEK | -14.74% |
| 2018 Q2 | 5.34 Million SEK | 20.48% |
| 2018 FY | 24.64 Million SEK | 86.89% |
| 2018 Q3 | 6.47 Million SEK | 21.07% |
| 2018 Q1 | 4.43 Million SEK | 2.05% |
| 2018 Q4 | 8.37 Million SEK | 29.33% |
| 2017 Q3 | 3.25 Million SEK | 12.2% |
| 2017 Q1 | 2.63 Million SEK | 0.0% |
| 2017 Q2 | 2.9 Million SEK | 10.05% |
| 2017 Q4 | 4.35 Million SEK | 33.64% |
| 2017 FY | 13.18 Million SEK | 8.14% |
| 2016 FY | 12.19 Million SEK | 46792.31% |
| 2015 FY | 26 Thousand SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Simris Alg AB (publ) | 38.64 Million SEK | -3.897% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 87.513% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 88.774% |
| Xintela AB (publ) | 57.31 Million SEK | 29.953% |
| Active Biotech AB (publ) | 44.8 Million SEK | 10.402% |
| Amniotics AB (publ) | 29.07 Million SEK | -38.099% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -173.992% |
| BioArctic AB (publ) | 89.62 Million SEK | 55.205% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 97.349% |
| Camurus AB (publ) | 1.05 Billion SEK | 96.211% |
| Cantargia AB (publ) | 290.01 Million SEK | 86.157% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -83.366% |
| CombiGene AB (publ) | 44.14 Million SEK | 9.052% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 71.922% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -41.734% |
| Genovis AB (publ.) | 88.19 Million SEK | 54.479% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 65.111% |
| Mendus AB (publ) | 129.13 Million SEK | 68.911% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -452.394% |
| Intervacc AB (publ) | 79.78 Million SEK | 49.68% |
| Kancera AB (publ) | 63.07 Million SEK | 36.351% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -627.451% |
| LIDDS AB (publ) | 27.75 Million SEK | -44.667% |
| Lipum AB (publ) | 37.3 Million SEK | -7.615% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -453.46% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 70.46% |
| NextCell Pharma AB | -576.01 Thousand SEK | 7069.909% |
| OncoZenge AB (publ) | 15.9 Million SEK | -152.424% |
| Saniona AB (publ) | 1.07 Million SEK | -3627.762% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 77.908% |
| Ziccum AB (publ) | 27.87 Million SEK | -44.013% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -144.79% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 86.926% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 5.827% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -127.043% |
| Corline Biomedical AB | 30.16 Million SEK | -33.081% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 30.816% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 51.727% |
| Aptahem AB (publ) | 10.01 Million SEK | -300.961% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 70.193% |
| Fluicell AB (publ) | 28.61 Million SEK | -40.294% |
| Biovica International AB (publ) | 133.72 Million SEK | 69.977% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -102.87% |
| AcouSort AB (publ) | 25.87 Million SEK | -55.155% |
| Abliva AB (publ) | 27.86 Million SEK | -44.075% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 79.252% |
| 2cureX AB (publ) | 36.51 Million SEK | -9.94% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 95.329% |
| Cyxone AB (publ) | 28.21 Million SEK | -42.298% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 63.291% |
| Biosergen AB | 26.8 Million SEK | -49.756% |
| Nanologica AB (publ) | 69.88 Million SEK | 42.553% |
| SynAct Pharma AB | 224.49 Million SEK | 82.116% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 9.118% |
| BioInvent International AB (publ) | 441.4 Million SEK | 90.904% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -67.603% |
| Alzinova AB (publ) | 36.39 Million SEK | -10.309% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 86.144% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -411.031% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 63.803% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -173.116% |